| Code | CSB-RA011626MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to melrilimab, specifically targeting IL1RL1 (also known as ST2), a member of the interleukin-1 receptor family. IL1RL1 exists in both transmembrane and soluble forms and serves as the receptor for IL-33, playing a crucial role in type 2 immune responses and inflammatory signaling pathways. Upon IL-33 binding, IL1RL1 activates downstream signaling cascades that promote the production of pro-inflammatory cytokines and chemokines. Dysregulated IL1RL1/IL-33 signaling has been implicated in various pathological conditions including asthma, allergic diseases, cardiovascular disorders, fibrotic diseases, and certain cancers, making it an important therapeutic target.
Melrilimab represents a therapeutic antibody designed to modulate IL1RL1 signaling, with particular interest in inflammatory and fibrotic conditions. This biosimilar provides researchers with a valuable tool for investigating IL1RL1-mediated immune responses, exploring the IL-33/ST2 axis in disease pathogenesis, and evaluating potential therapeutic interventions in preclinical models. The antibody enables detailed studies of type 2 immunity and inflammatory mechanisms across diverse research applications.
There are currently no reviews for this product.